Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand

References

• World Health Organization. The global burden of disease: 2004 update. 2004
   Google Scholar
• Khuhaprema T, Srivatanakul P, Sriplung H, et al. Cancer in Thailand 2001-2003 Vol.V. 2001-2003. 2003
   Google Scholar
• Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis colon Rectum 1997;40:15-24
   PubMed Web of Science ®Google Scholar
• Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from national surgical adjuvant breast and bowel project protocol C-03. J Clin Oncol 1993;11:1879-87
   PubMed Web of Science ®Google Scholar
• O’Connell M, Mailliard J, Kahn M, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997;15:246-50
   PubMed Web of Science ®Google Scholar
• Gra’valos C, Garci’a-Escobar I, Garci’a-Alfonso P, et al. Adjuvant chemotherapy for stage II,III and IV of colon cancer. Clin Transl Oncol 2009;11:526-33
   Google Scholar
• Twelves C, Wong A, Nowacki M, et al. Capecitabine as adjuvant treatment for colon cancer. N Engl J Med 2005;352:2696-704
   PubMed Web of Science ®Google Scholar
• Thierry A, Corrado B, Lamia M, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343-51
   Google Scholar
• Kueble J, Samuel WH, Michael J, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results From NSABP C-07. J Clin Oncol 2007;25:2198-204
   Google Scholar
• Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: mechanism of action and antineoplastic activity Semin Oncol. 1998;25(suppl5):4-12
   Google Scholar
• Riewpaiboon A. Measure of costs. J med Assoc Thai 2008;91(suppl 2):S28-37
   Google Scholar
• Permsuwan U, Guntawongwan K, Buddhawongsa P. Handling time in economic evaluation studies. J Med Assoc Thai 2008;91(suppl 2):S53-8
   PubMedGoogle Scholar
• The Subcommittee for Development of the National List of Essential Medicines. The threshold at which an intervention becomes cost-effective meeting of the Subcommittee for Development of the National List of Essential Medicine. 9/2007, 20 December 2007; Jainad Narendhorn meeting room, Thai Food and Drug Administration, Ministry of Public Health, Thailand
   Google Scholar
• The Commission on Macroeconomics and Health. Macroeconomics and Health. Investing in Health for Economic Development. Geneva: World Health Organization; 2002
   Google Scholar
• Ministry of Commerce Thailand. Report for Consumer Price Index of Thailand year. 2009
   Google Scholar
• Rates of Exchange of Commercial Banks in Bangkok Metropolis. Available from: www2.bot.or.th/statistics/ReportPage.aspx?reportID=123&language=eng
   Google Scholar
• PPP conversion factor, private consumption. Available from: http://data.worldbank.org/indicator/PA.NUS.PRVT.PP
   Google Scholar
• Reference drug price during April-June 2010. Available from: http://dmsic.moph.go.th/download/rp_4-6_52.pdf
   Google Scholar
• Ministry of Public Health. Reimbursement rate of public health facilities. Nonthaburi: Ministry of Public Health Ministry of Public Health; 2004
   Google Scholar
• Haller DG, Cassidy J, Tabernero J, et al. Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (N016968): No impact of age on disease-free survival (DSF). Gastrointestinal Cancers Symposium 2010
   Google Scholar
• Diao C, Cheng RC, Zhang JM, et al. Clinical observation of XELOX (Capecitabine plus Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer. Zhonghua Zhong Liu Za Zhi 2008;30(2):147-50
   Google Scholar
• Daniel GH, Josep T, Jean M, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011;29(11):1465-71
   Google Scholar
• Comella P, Massidda G, Palmeri S, et al. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial. Ann Oncol 2005;16:878-86
   PubMedGoogle Scholar
• Cunningham D, Sirohi B, Pluzanska A, et al. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Annal Oncol 2009;20:244-50
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M. Leucovorin and fuorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7
   PubMed Web of Science ®Google Scholar
• Eduardo D, Jose T, Gómez-España A, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish cooperative group for the treatment of digestive tumors trial. J Clin Oncol 2007;25(27):4224-30
   Google Scholar
• Eric VC, Chris T, Jim C, et al. Oral Capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-106
   Google Scholar
• Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18(1):137-47
   Google Scholar
• Giuseppe C, Vittorio G, Giancarlo P, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol 2005;23(22):4866-75
   Google Scholar
• Hanna KS, Daniel JS, Megan EC, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer. J Clin Oncol 2008;26(35):5721-7
   Google Scholar
• Hospers GA, Schaapveld M, Nortier JW, et al. Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer. Annal Oncol 2006;17:443-9
   Google Scholar
• Kohne CH, van CE, Bokemeyer C, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients metastatic colorectal cancer: European organization for research and treatment of cancer gastrointestinal group study. J Clin Oncol 2005;23:4856-65
   PubMed Web of Science ®Google Scholar
• Leonard BS, John VC, Charies B, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-14
   Google Scholar
• Matthew TS, Timothy SM, Jonathan AL, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007;370(9582):143-52
   Google Scholar
• Michael D, Jaafar B, Mohamed H, et al. Capecitabine plus oxaliplatin (xelox) versus 5-fluorouracil/leucovorin plus oxaliplatin(folfox-6) as first-line treatment for metastatic colorectal cancer. Inter J Can 2010;1-9
   Google Scholar
• Pasquale C, Bruno M, Gianfranco F, et al. Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study. J Cancer Res Clin Oncol 2009;135(2):217-26
   Google Scholar
• Paulo MH, Rafat Ai, Gerald B, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19(8):2282-92
   Google Scholar
• Rainer P, Hendrik-Tobias A, Stephan K, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO colorectal study group. J Clin Oncol 2007;25(27):4217-23
   Google Scholar
• Richard MG, Daniel JS, Roscoe FM, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006;21(21):3347-53
   Google Scholar
• Brooks R. EuroQol Group: EuroQol: the current state of play. Health Policy 1996;37:53-72
   PubMed Web of Science ®Google Scholar
• Kind P. The EuroQol instrument; an index of health-related quality of life. Philadelphia: Lippincott-Raven; 1996
   Google Scholar
• Ramsey S, Andersen MR, Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Am Can Soc 2000;1294-303
   Google Scholar
• Limwattananon S. Handling uncertainty of the economic evaluation result: sensitivity analysis. J Med Assoc Thai 2008(Suppl(2):S59-65
   Google Scholar
• Aballea S, Boler A, Craigc A, Wasan H. An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK). Eur J Can 2007;43:1687-93
   PubMed Web of Science ®Google Scholar
• Aballea S, Jeremy VM, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 2007;109(6):1082-9
   PubMed Web of Science ®Google Scholar
• Eggington S, Tappenden P, Pandor A, et al. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. Br J Cancer 2006;95:1195-201
   PubMed Web of Science ®Google Scholar
• The Subcommittee for Development of the National List of Essential Medicines: The consideration of oxaliplatin meeting of the Subcommittee for Development of the National List of Essential Medicine. 5/2555, 29 May 2012; Laungvichenpattayakom meeting room, Thai Food and Drug Administration, Ministry of Public Health, Thailand
   Google Scholar
• Koukourakis GV, Zacharias G, Tsalafoutas J, et al. Capecitabine for locally advanced and metastatic colorectal cancer: a review. World J Gastrointest Oncol 2010;2(8):311-21
   Google Scholar
• Wang F, Wang FH, Bai L, et al. Role of capecitabine in treating metastatic colorectal cancer in Chinese patients. Onco Targets Ther 2014;2(7):501-11
   Google Scholar
• Iwai M, Kimura M, Yoshimura T, Yasuda T. Side effect analyses in consideration of renal functions for capecitabine-administered patients. Gan To Kagaku Ryoho 2012;39(5):783-6
   Google Scholar
• Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085-91
   PubMed Web of Science ®Google Scholar
• Jackson McCleary NA, Meyerhardt J, Green E, et al. Impact of older age on the efficacy of newer adjuvant therapies in >12500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database. J Clin Oncol 2009;27(Suppl):15s
   Google Scholar
• Kim JY, Kim YJ, Lee KW, et al. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea. Jpn J Clin Oncol 2013;43(2):132-8
   Google Scholar